Mechanism of airway inflammation in asthma.

Airway inflammation has emerged as an important contributor to mechanisms of asthma. Furthermore, the presence of airway inflammation is present even in the absence of severe symptoms. To study the mechanisms by which bronchial inflammation can occur in asthma, a number of models have been developed including the airway response to antigen in allergic subjects. The pattern that has emerged from such studies indicates prompt pulmonary mast-cell activation and the apparent initiation of an inflammatory response. This inflammatory response develops over hours and is important in the later and more persistent development of bronchial obstruction. The eosinophil is an important cell in this process as are proinflammatory cytokines generated from activated lung mononuclear cells. The consequence of this multiple cell, multiple proinflammatory product interaction is the establishment of a self-perpetuating, redundant process by which asthma severity increases.

[1]  S. Durham,et al.  Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. , 1992, The New England journal of medicine.

[2]  W. Busse,et al.  Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge. Characterization of eosinophil and mast cell mediators. , 1991, The American review of respiratory disease.

[3]  P. Weller,et al.  The immunobiology of eosinophils. , 1991, The New England journal of medicine.

[4]  A. Kagey‐Sobotka,et al.  Prednisone inhibits the appearance of inflammatory mediators and the influx of eosinophils and basophils associated with the cutaneous late-phase response to allergen. , 1991, Journal of immunology.

[5]  S. Durham,et al.  Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. , 1990, The American review of respiratory disease.

[6]  J. Bousquet,et al.  Eosinophilic inflammation in asthma. , 1990, The New England journal of medicine.

[7]  J. Snapper.  Inflammation and airway function: the asthma syndrome. , 1990, The American review of respiratory disease.

[8]  G. Gleich.  The eosinophil and bronchial asthma: current understanding. , 1990, The Journal of allergy and clinical immunology.

[9]  R. Rothlein,et al.  Intercellular adhesion molecule-1 (ICAM-1) in the pathogenesis of asthma. , 1990, Science.

[10]  A. Wardlaw,et al.  Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. , 1989, The American review of respiratory disease.

[11]  P. Barnes,et al.  A new approach to the treatment of asthma. , 1989, The New England journal of medicine.

[12]  W. Owen,et al.  IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity. , 1989, Journal of immunology.

[13]  C. Wegner,et al.  Antigen-coated sepharose beads induce airway eosinophilia and airway hyperresponsiveness in cynomolgus monkeys. , 1989, The American review of respiratory disease.

[14]  P. Barnes,et al.  New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma. , 1989, The Journal of allergy and clinical immunology.

[15]  C. Heusser,et al.  Production of the haemopoietic growth factors GM-CSF and interleukin-3 by mast cells in response to IgE receptor-mediated activation , 1989, Nature.

[16]  W. Paul,et al.  Mast cell lines produce lymphokines in response to cross-linkage of FcεRI or to calcium ionophores , 1989, Nature.

[17]  S. Holgate,et al.  Cellular events in the bronchi in mild asthma and after bronchial provocation. , 1989, The American review of respiratory disease.

[18]  W. Busse,et al.  Respiratory infections: their role in airway responsiveness and the pathogenesis of asthma. , 1990, The Journal of allergy and clinical immunology.

[19]  D. W. Cockcrofte.  Airway Hyperresponsiveness and Late Asthmatic Responses , 1988 .

[20]  W. Owen,et al.  Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. , 1988, The Journal of clinical investigation.

[21]  K. Chung,et al.  Inflammatory mediators and asthma. , 1988, Pharmacological reviews.

[22]  J. Gamble,et al.  Recombinant human interleukin 5 is a selective activator of human eosinophil function , 1988, The Journal of experimental medicine.

[23]  P. O'Byrne,et al.  Late asthmatic responses. , 1987, The American review of respiratory disease.

[24]  M. Kaliner,et al.  Neutrophils and mast cells. I. Human neutrophil-derived histamine-releasing activity. , 1987, Journal of immunology.

[25]  L. Fabbri,et al.  Bronchoalveolar neutrophilia during late asthmatic reactions induced by toluene diisocyanate. , 1987, The American review of respiratory disease.

[26]  H. S. Earl,et al.  Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. , 1987, The New England journal of medicine.

[27]  A. Togias,et al.  Inflammatory mediators in late antigen-induced rhinitis. , 1985, The New England journal of medicine.

[28]  S. Holgate,et al.  Mast cells, mediators and asthma , 1985, Clinical allergy.

[29]  T. Haahtela,et al.  Damage of the airway epithelium and bronchial reactivity in patients with asthma. , 1985, The American review of respiratory disease.

[30]  H. Sluiter,et al.  Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. , 1985, The American review of respiratory disease.

[31]  E D Robin,et al.  Total eosinophil counts in the management of bronchial asthma. , 1975, The New England journal of medicine.